Femasys Inc (FEMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Femasys Inc (FEMY) has a cash flow conversion efficiency ratio of -0.568x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.14 Million) by net assets ($7.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Femasys Inc balance sheet independence to measure how much of total assets are equity-financed.
Femasys Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Femasys Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Femasys Inc to evaluate the quality of earnings relative to operating cash generation.
Femasys Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Femasys Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Renew Holdings plc
LSE:RNWH
|
0.122x |
|
COSCIENS Biopharma Inc.
NASDAQ:CSCI
|
-0.627x |
|
Green Earth Group N.V.
AS:HWK
|
0.038x |
|
Pursuit Minerals Ltd
AU:PUR
|
-0.019x |
|
Thai Nondestructive Testing Public Company Limited
BK:TNDT
|
0.066x |
|
Australian Dairy Nutritionals Ltd
AU:AHF
|
-0.080x |
|
ES Energy Save Holding AB
ST:ESGR-B
|
0.022x |
|
Auriginal Mining Corp.
V:AUME
|
-0.158x |
Annual Cash Flow Conversion Efficiency for Femasys Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Femasys Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Femasys Inc (FEMY) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.87 Million | $-18.69 Million | -3.184x | +62.26% |
| 2024-12-31 | $2.30 Million | $-19.44 Million | -8.438x | -1272.75% |
| 2023-12-31 | $18.35 Million | $-11.28 Million | -0.615x | +12.70% |
| 2022-12-31 | $15.24 Million | $-10.73 Million | -0.704x | -133.77% |
| 2021-12-31 | $26.33 Million | $-7.93 Million | -0.301x | +78.46% |
| 2020-12-31 | $3.53 Million | $-4.93 Million | -1.398x | -676.44% |
| 2019-12-31 | $-45.37 Million | $-11.01 Million | 0.243x | -- |
About Femasys Inc
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal pat… Read more